Magnetic Insight

Magnetic Insight introduced the first new modality and transformational advancement in medical imaging in over 30 years

Business Summary: Magnetic Insight (MI) introduced magnetic particle imaging into the preclinical diagnostic research market ($800M TAM) enabling quantitative cell tracking, imaging of vascular function, detecting metastatic tumors, visualizing inflammation, CAR-T cell therapies and initial research into regenerative medicine. Premier global research institutions are lining up to secure their place in line following the breakthroughs pioneered by researchers at Stanford with the initial commercial (and paid) installation. Problem: The pre-clinical research and clinical markets have unmet needs in quantitative cell tracking, monitoring vascular function, and visualizing the immune system, among others. Currently, optical imaging has the largest user base but serious limitations to clinical translation. PET and SPECT imaging require radioisotopes and long-term studies are limited due to isotopes half-life. Clinically, there is a severe need in neuroradiology as CT angiography protocols are being reduced due to excessively high radiation and toxicities associated with Iodine and MRI gadolinium. Perfusion imaging suffers severe data clarity challenges with current technologies. Solution: Magnetic Insight’s MPI solution developed over 10+ years detects iron oxide tracers with high sensitivity deep in the body. MI’s solution solves significant safety and diagnostic precision challenges by utilizing nanoparticle detection. MI delivers high contrast, fast and quantitative images with the tracers delivering comparable contrast to PET and SPECT, without radiation or gadolinium. MI’s second product, a clinical neurovascular imager ($5B TAM), addresses unmet needs of neuroradiologists in perfusion imaging and will be available in the next 4 years. Scalable clinical markets in breast, lung, kidney and interventional imaging will be achieved with modified designs. Business Model: Magnetic Insight offers a diversified revenue model of scanner and reoccurring reagent sales along with full application service/support and training revenues.